# STUDY ON THE PREVENTION OF CARDIOVASCULAR EVENTS BY ANTIPLATELET AGENTS AFTER ACUTE CORONARY SYNDROME (AREMIS)

First published: 04/03/2014 Last updated: 01/02/2017





### Administrative details

<b>EU PAS number</b>		
EUPAS5905		
Study ID		
17589		
DARWIN EU® study		
No		
Study countries		
France		

**Study description** 

The Primary objective of this study is to compare the relative risk of new myocardial infarction (MI) or cardiac death in patients with a history of acute coronary syndrome ('ACS': unstable angina or myocardial infarction), using ticagrelor, clopidogrel or prasugrel (if applicable) or none of these treatments, where aspirin is considered a covariate. Secondary objectives include the estimation of the incidence rates among patients with a history of acute coronary syndrome (unstable angina or myocardial infarction), exposed to the use of ticagrelor, clopidogrel, prasugrel, or none of these treatments, of the following events: recurrent myocardial infarction (rMI), stroke, major bleeding (requiring hospitalization) and non-major and death, to describe patterns of use for ticagrelor and other antiplatelet agents (indication, substitutions, etc.), including the discontinuation of treatment and reasons, and to study the influence of risk factors on the risk of cardiovascular events in participating patients and assess how these factors interact with ticagrelor and other antiplatelet drugs. The study design is a general cohort of patients with acute coronary syndrome (ACS) followed for 12 months for the occurrences of interest. A case-cohort analysis will compare drug exposure between patients who have had an occurrence of interest to those who did not (population-time with no event). Medical information at baseline is entered by cardiologists in the PGRx system. Drug exposure is obtained from cardiologists and patients through standardized and validated telephone interviews. Events of interest are examined by an adjudication committee. A total of 3,750 patients with ACS will be needed to achieve a power of 80% to detect an Odds ration inferior to 0.8 for the comparison ticagrelor to the each of clopidogrel and prasugrel, assuming approximately equal exposure in the population of interest.

### **Study status**

Ongoing

### Research institutions and networks

# Institutions

Real World Studies, LA-SER Research
France
United Kingdom
First published: 23/03/2012
Last updated: 23/03/2012
Institution Outdated Other ENCePP partner

### **Networks**

PGRx®
France
United Kingdom
First published: 30/03/2010
<b>Last updated:</b> 17/01/2012
Network Outdated ENCePP partner

## Contact details

### Study institution contact

Lamiae Grimaldi lamiae.grimaldi@la-ser.com

Study contact

lamiae.grimaldi@la-ser.com

### **Primary lead investigator**

### Lamiae Grimaldi

**Primary lead investigator** 

### Study timelines

#### Date when funding contract was signed

Planned: 23/11/2012

### Study start date

Planned: 01/09/2013

Actual: 04/10/2013

#### **Date of final study report**

Planned: 20/12/2016

## Sources of funding

• Pharmaceutical company and other private sector

### More details on funding

Astra-Zeneca

### Regulatory

#### Was the study required by a regulatory body?

Yes

### Is the study required by a Risk Management Plan (RMP)?

Not applicable

### Methodological aspects

# Study type

# Study type list

#### Study type:

Non-interventional study

### Scope of the study:

Effectiveness study (incl. comparative)

#### Main study objective:

The Primary objective of this study is to compare the relative risk of new myocardial infarction (MI) or cardiac death in patients with a history of acute coronary syndrome ('ACS': unstable angina or myocardial infarction), using ticagrelor, clopidogrel or prasugrel (if applicable) or none of these treatments, where aspirin is considered a covariate.

# Study Design

#### Non-interventional study design

Other

### Non-interventional study design, other

Case-cohort study

### Study drug and medical condition

#### **Anatomical Therapeutic Chemical (ATC) code**

(B01AC) Platelet aggregation inhibitors excl. heparin Platelet aggregation inhibitors excl. heparin

#### Medical condition to be studied

Myocardial infarction

Acute coronary syndrome

# Population studied

#### Age groups

- Adults (18 to < 46 years)</li>
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)
- Adults (75 to < 85 years)
- Adults (85 years and over)

#### **Estimated number of subjects**

3750

### Study design details

#### **Outcomes**

The recurrent myocardial infarction (rMI) or cardiac death, Stroke, major (requiring hospitalization) and non-major bleeding, and death

#### **Data analysis plan**

Analyses will follow that of a matched case control study where cases are identified prospectively in a cohort and matched at each time point of occurrence to available controls in the cohort (without the events of interest), for age, sex and type of ACS at entry in the cohort (angina or MI). Odds ratios will be calculated using conditional logistic regression. All risk factors will be documented for cases and referents, which will be compared regarding the use of ticagrelor vs. clopidogrel or vs. prasugrel (in PCI if its use is sufficient). An adjusted odds ratio will be estimated in each case. Secondary analysis, using the cohort of reference will historically estimate the incidence of rMI, stroke and bleeding from the time of the occurrence of 'index' acute coronary syndrome up to 12 months after the ACS. The incidence rates of recurrent MI, stroke, death and bleeding will be produced, with their confidence intervals, by antiplatelet therapy.

### Data management

### **ENCePP Seal**

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

#### Composition of steering group and observers

AReMIS CS Contact list 30092013.pdf (109.15 KB)

### Data sources

### **Data sources (types)**

Other

### Data sources (types), other

Case-control surveillance database

### Use of a Common Data Model (CDM)

#### **CDM** mapping

No

### Data quality specifications

#### **Check conformance**

Unknown

#### **Check completeness**

Unknown

#### **Check stability**

Unknown

### **Check logical consistency**

Unknown

### Data characterisation

### **Data characterisation conducted**

No